Bromocriptine

When ATH:
N04BC01

Characteristic.

Semi-synthetic derivative of ergot alkaloid ergocryptine (2-bromo-alpha-ergocryptine). Crystalline powder, very slightly soluble in water, sparingly soluble ethanol.

Pharmacological action.
Antiparkinsonian.

Application.

Infertility and dysmenorrhea in the background of overproduction of prolactin, insufficiency of the luteal phase, hyperprolactinemia (incl. as a result of receiving antihypertensive drugs and psychotropic), prolaktinomy (Syndrome of persistent galactorrhea-amenorrhea in women and hypogonadism in men), postpartum lactation (if necessary, its suppression), premenstrual syndrome, akromegalija, benign breast disease, benign nodular and / or cystic changes in the breast, incl. shotty breast; Parkinson's disease, parkinsonizm.

Contraindications.

Hypersensitivity, gestosis, diseases of the cardiovascular system, arterïalnaya hypo- or hypertension, recent myocardial infarction, valvular disease in history, expressed arrhythmias, endogenous psychosis, hepatic failure.

Restrictions apply.

Erosive and ulcerative lesions of the gastrointestinal tract, pregnancy (I trimester).

Pregnancy and breast-feeding.

Category actions result in FDA - B. (The study of reproduction in animals revealed no risk of adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not done.)

Side effects.

Nausea, vomiting, dry mouth, constipation, decrease in blood pressure, whitening of the fingers and toes when cooled, headache, dizziness, drowsiness, excitation, reduced visual acuity, swelling of the mucous membranes, nasal congestion, allergic reactions, cramps in the calf muscles; seldom-ortostatical gipotenzia, collapse.

Cooperation.

Incompatible with MAO inhibitors and alcohol. It reduces the effect of neuroleptics, oral contraceptives, reduces akinesia, reserpine-induced.

Overdose.

Overdose. Symptoms: headache, hallucinations, decrease in blood pressure.

Treatment: parenteral administration of metoclopramide.

Dosing and Administration.

Inside, while eating. The mode set individually, depending on the evidence. The initial single dose of 1.25-2.5 mg 1-3 times a day. The average therapeutic doses for mono- and combination therapies accounted for 10-30 mg/day.

Precautions.

It is recommended that periodic monitoring of blood pressure, liver and kidney function.

Before the treatment of benign breast diseases to rule out a malignant tumor of the same location.

Be wary appoint persons, whose work requires attention and speed of decision-making.

Cooperation